Human antibodies produced in lab to treat diseases

Image
IANS London
Last Updated : Jul 24 2017 | 8:32 PM IST

Scientists have developed a method to artificially produce specific human antibodies which can be used to treat a wide range of diseases and facilitate the development of new vaccines.

A team of researchers led by Facundo Batista of Francis Crick Institute in London and Ragon Institute of MGH, MIT, and Harvard have been able to produce specific human antibodies in the laboratory.

The technique, described in a paper published on Monday in 'The Journal of Experimental Medicine', could speed the production of antibodies by body's 'B-cells' that fight off infections by bacteria, viruses, and other invasive pathogens.

"Specifically, it should allow the production of these antibodies within a shorter time frame 'in vitro' and without the need for vaccination or blood/serum donation from recently infected or vaccinated individuals," said Batista.

Apart from specific antigen, 'B-cells' also need DNA fragments called 'CpG Oligonucleotides' to start proliferating and developing into plasma cells, which the team has managed to produce.

"Our method offers the potential to accelerate the development of new vaccines by allowing the efficient evaluation of candidate target antigens," he added.

The team successfully demonstrated their approach using various bacterial and viral antigens including the tetanus toxoid and proteins from several strains of 'influenza A'.

In each case, they were able to produce specific, high-affinity antibodies in just a few days. Some of the anti-influenza antibodies generated by the technique recognised multiple strains of the virus and were able to neutralise its ability to infect cells.

The procedure does not depend on the donors having been previously exposed to any of these antigens through vaccination or infection.

The researchers were able to generate anti-HIV antibodies from 'B-cells' isolated from HIV-free patients.

--IANS

sau/pgh/dg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 24 2017 | 8:24 PM IST

Next Story